Die Suchmaschine für Unternehmensdaten in Europa
Transparenzregister der Europäischen Union Eutr 17.01.2026 Transparenzregister der Europäischen Union
Auf einen Blick
Text
EU Transparency Register Entry
Export Date: 2026-11-03T21:00:00.021+00:00 Number of Interest Representatives: 18028
Interest Representative Details
- Identification Code: 5307288102066-54
- Registration Date: 2026-01-12T13:05:50.526+00:00
- Name: Genmab A/S
- Entity Form: aktieselskab
- Website: https://www.genmab.com/
- Registration Category: Companies & groups
- Goals: To help people living with cancer and other serious diseases.
Head Office
- Address: Carl Jacobsens Vej 30, 2500 Valby, DENMARK
- Phone: +45 70202728
EU Office
- Address: Carl Jacobsens Vej 30, 2500 Valby, DENMARK
- Phone: +45 70202728
Levels of Interest
- Global
- European
- National
- Sub-national
EU Legislative Proposals
Genmab intends to engage constructively and transparently in the implementation of the EU regulation on joint clinical health technology assessments (EU HTA) and in the political and regulatory process surrounding the upcoming Biotech Act. The purpose is to contribute professional knowledge and practical experience to support a well-functioning European framework that both strengthens patient access to innovative treatments and supports Europe's long-term competitiveness in biotechnology.
The EU HTA regulation marks a significant step towards a more harmonized European system for clinical assessment of new medicines. Implementation will affect how clinical evidence is developed, assessed, and used in national decision-making processes regarding pricing and reimbursement. Genmab develops advanced, targeted therapies for the treatment of serious diseases, often in smaller and well-defined patient populations. In this context, it is essential that the common methodological frameworks for clinical assessment are scientifically robust, flexible, and adapted to the rapid development in modern biotechnology, including the use of biomarkers, innovative study designs, and limited datasets for rare or serious diseases. Genmab's engagement aims to support an implementation that promotes predictability, quality, and coherence between the common European level and national processes.
The Biotech Act is similarly expected to have a major impact on the structural framework conditions for biotechnological research, development, and production in Europe. The initiative is seen as an opportunity to strengthen Europe's position as an attractive location for innovation, investment, and industrial capacity in advanced biological medicines. For Genmab, it is central that future initiatives contribute to coherent and competitive frameworks across regulation, research, industry, and health policy. A clear, long-term, and investment-friendly environment is crucial for companies to continue to develop new treatments in Europe for the benefit of patients and healthcare systems.
Genmab's involvement in these processes will be based on open dialogue, fact-based contributions, and respect for the role and mandate of the European institutions. The company wishes to share experiences from the development, clinical documentation, and market access for innovative medicines and thereby contribute to a common understanding of how political and regulatory choices are translated into practice. The engagement has a long-term perspective and is based on a desire to contribute positively to a sustainable European health and innovation ecosystem.
Overall, Genmab sees the work on EU HTA implementation and the Biotech Act as important elements in the development of a more coherent, effective, and future-oriented European framework. Early and constructive involvement provides an opportunity to identify potential challenges and contribute to solutions that balance the healthcare systems' need for solid documentation and responsible resource utilization with the need for continued innovation. The objective is to support faster and more uniform access to new treatments for patients in Europe, while strengthening Europe's position as a global center for biotechnological innovation.
Inter or Unofficial Groupings
N/A
Members
- Number of members (25%):
? - Total members: 1.0
- FTE (Full-Time Equivalent) members: 0.25
- Additional Information on Members:
EP Accredited Number
?
Interests
- Business and industry
- Competition
- Public health
- Research and innovation
Structure
- Organisation Members: EUCOPE
Interest Represented
Promotes their own interests or the collective interests of their members
Financial Data
- New Organisation: No
Closed Year (2025-02-01 to 2026-01-01)
- Costs: €25,000 - €49,999
- Intermediaries: None
- Grants: None
Current Year
- Intermediaries: None
- Grants: None
Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: Genmab A/S, Valby, Dänemark.